Drugs

Robert Jotte presents how Adagrasib shows improvement in PFS and ORR in previously treated patients – Sarah Cannon Research Institute

Photo of Robert Jotte from rockymountaincancercenters.com

Jul 1, 2024, 14:03

Robert Jotte presents how Adagrasib shows improvement in PFS and ORR in previously treated patients – Sarah Cannon Research Institute

Sarah Cannon Research Institute shared on LinkedIn:

“Significant advancements in NSCLC treatment! SCRI’s Dr. Robert Jotte presents how Adagrasib shows improvement in PFS and ORR over Docetaxel in previously treated patients. Watch his detailed discussion on ecancer.”

Source: Sarah Cannon Research Institute/LinkedIn

Adagrasib ASCO24 cancer Cancer research clinical trials docetaxel ecancer immunotherapy NSCLC NSCLC treatment OncoDaily Oncology ORR PFS Robert Jotte Sarah Cannon Research Institute

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage